Learning from HSV-infected mice as a model of Behçet's disease

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Sohn, Seonghyang ^a   Lee, Eun So ^a   Bang, Dongsik ^b  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Animal model; Application; Beh et's disease; Herpes simplex virus

Indexed keywords

ACICLOVIR; CALCITRIOL; COLCHICINE; ETANERCEPT; FAMCICLOVIR; GEMCITABINE; HLA B51 ANTIGEN; HLA G ANTIGEN; INFLIXIMAB; INTERLEUKIN 6; MESSENGER RNA; PENCICLOVIR; REBAMIPIDE; RETINA S ANTIGEN; SMALL INTERFERING RNA; THALIDOMIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

BEHCET DISEASE; CD4+ CD25+ T LYMPHOCYTE; CELL TRANSFER; CELLULAR IMMUNITY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENTERITIS; GENETIC RISK; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HUMAN; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOSAL DISEASE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SKIN DEFECT; SOLID TUMOR; TH1 TH2 BALANCE; ANIMAL; DISEASE COURSE; DRUG EFFECT; GENETICS; HERPES SIMPLEX VIRUS 1; IMMUNOLOGY; MOUSE; PATHOGENICITY; PATHOLOGY; RISK FACTOR; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BEHCET SYNDROME; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; RISK FACTORS;

EID: 84873252910     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Alpsoy E, Zouboulis Cc, Ehrlich Ge: Mucocutaneous Lesions Of Behçet'S Disease. Yonsei Med J 2007;48:573-585.
2. HORI Y, Miyazawa S, Nishiyama S, Miyata M, Ishikawa S: Experimental Behçet'S Disease And Ultrastructural X-Ray Microanalysis Of Pathological Tissues. J Dermatol 1979;6:31-37.
3. STANFORD MR, Kasp E, Whiston R Et Al.: Heat Shock Protein Peptides Reactive In Patients With Behçet'S Disease Are Uveitogenic In Lewis Rats. Clin Exp Immunol 1994;97:226-231.
4. TAKENO M, Kariyone A, Yamashita N Et Al.: Excessive Function Of Peripheral Blood Neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995;38:426-433.
5. OHNO S, OHGUCHI M, HIROSE S, MATSUDA H, WAKISAKA A, AIZAWA M: Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982;100:1455-1458.
6. BAHARAV E, MOR F, HALPERN M, QUINTANA F, WEINBERGER A: Tropomyosin-induced arthritis in rats. Clin Exp Rheumatol 2007;25(Suppl. 45):S86-S92.
7. DJERABA Z, ARROUL-LAMMALI A, MEDJEBER O et al.: Nitric oxide, biomarker of experimental autoimmune uveitis induced by S antigen. J Fr Ophtalmol 2010;33:693-700.
8. Behçet H: Ueber rezidivierende, aphthoese durch ein Virus verursachte Geschwuere am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937;105:1152-1157.
9. SEZER FN: The isolation of a virus as the cause of Behçet's diseases. Am J Ophthalmol 1953;36:301-315.
10. EVANS AD, PALLIS CA, SPILLANE JD: Involvement of the nervous system in Behçet's syndrome; report of three cases and isolation of virus. Lancet 1957;273:349-353.
11. MORTADA A, IMAM IZ: Virus aetiology of Behçet's syndrome. Br J Ophthalmol 1964;48:250-259.
12. EGLIN RP, LEHNER T, SUBAK-SHARPE JH: Detection of RNA complementary to herpessimplex virus in mononuclear cells from patients with Behçet's syndrome and recurrent oral ulcers. Lancet 1982;2:1356-1361.
13. BONASS WA, BIRD-STEWART JA, CHAMBERLAIN MA, HALIBURTON IW: Molecular studies in Behçet's syndrome: Recent advances in Behçet's disease. London, Royal Society of Medicine Services Limited 1986;37-41.
14. DENMAN AM, PELTON BK, HYLTON W, PALMER RG, TOPPER R: Herpes simplex virus and the rheumatic diseases. Rheumatol Int 1989;9:143-146.
15. STUDD M, MCCANCE DJ, LEHNER T: Detection of HSV-1 DNA in patients with Behçet's syndrome and in patients with recurrent oral ulcers by the polymerase chain reaction. J Med Microbiol 1991;34:39-43.
16. LEE S, BANG D, CHO YH, LEE ES, SOHN S: Polymerase chain reaction reveals herpes simplex virus DNA in saliva of patients with Behçet's disease. Arch Dermatol Res 1996;288:179-183.
17. SOHN S, LEE ES, BANG D, LEE S: Behçet's disease-like symptoms induced by the Herpes simplex virus in ICR mice. Eur J Dermatol 1998;8:21-23.
18. SOHN S, LEE ES, LEE S: The correlation of MHC haplotype and development of Behçet's disease-like symptoms induced by herpes simplex virus in several inbred mouse strains. J Dermatol Sci 2001;26:173-181.
19. ELLIS SA, SARGENT IL, REDMAN CW, MCMICHAEL AJ: Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line. Immunology 1986;59:595-601.
20. KOVATS S, MAIN EK, LIBRACH C, STUBBLEBINE M, FISHER SJ, DEMARS R: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-223.
21. MCMASTER MT, LIBRACH CL, ZHOU Y et al.: Human placental HLA-G expression is restricted to differentiated cytotrophoblasts. J Immunol 1995;54:3771-3778.
22. RITEAU B, ROUAS-FREISS N, MENIER C, PAUL P, DAUSSET J, CAROSELLA ED: HLAG2, -G3 and -G4 isoforms expressed as nonmature cell-surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001;166:5018-5026.
23. DORLING A, MONK NJ, LECHLER RI: HLAG inhibits the transendothelial migration of human NK cells. Eur J Immunol 2000;30:586-593.
24. KANAI T, FUJII T, UNNO N et al.: Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood. Am J Reprod Immunol 2001;45:94-99.
25. RITEAU B, MENIER C, KHALIL-DAHER I et al.: HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999;43:203-211.
26. + T lymphocytes. J Reprod Immunol 2000;48:17-26.
27. PARK KS, NAM JH, LEE ES, CHOI JS, BANG D, LEE S: Increased risk of human leukocyte antigen-G gene variants in Behçet's disease. Clin Exp Rheumatol 2006;24:S126-S127.
28. PARK KS, PARK JS, NAM JH, BANG D, SOHN S, LEE ES: HLA-E*0101 and HLA-G*010101 reduce the risk of Behçet's disease. Tissue Antigens 2007;69:139-144.
29. MIZUKI N, MEGURO A, OTA M et al.: Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010;42:703-706.
30. EMMI L, BRUGNOLO F, MARCHIONE T: Pathogenesis and therapy of Behçet's disease. Ann Ital Med Int 1997;12:20-25.
31. RAZIUDDIN S, AL-DALAAN A, BAHABRI S, SIRAJ AK, AL-SEDAIRY S: Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998;25:329-333.
32. DESMEDT M, ROTTIERS P, DOOMS H, FIERS W, GROOTEN J: Macrophages induce cellular immunity by activating Th1 cell responses and suppressing Th2 cell responses. J Immunol 1998;160:5300-5308.
33. + T-cells in T-cell receptor transgenic NOD mice. Diabetes 1999;48:34-32.
34. SOHN S, LEE ES, KWON HJ, LEE SI, BANG D, LEE S: Expression of Th2 cytokines decreases the development of and improves Behçet's disease-like symptoms induced by herpes simplex virus in mice. J Infect Dis 2001;183:1180-1186.
35. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
36. CRISPIN JC, MARTINEZ A, VARELA JA: Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 2003;21:273-276.
37. AMELSFORT J, JACVOBS K, BIJLSMA J, LAFEBER F, TAAMS L: CD4+CD25+ regulatory T cells in rheumatoid arthritis: Difference in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004;50:2775-2785.
38. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
39. NANKE Y, KOTAKE S, GOTO M, UJIHARA H, MATSUBARA M, KAMATANI N: Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet's disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 2008;18:354-358.
40. + regulatory T cells ameliorate Behçet's disease-like symptoms in a mouse model. Cytotherapy 2011;13:835-847.
41. REMMERS EF, COSAN F, KIRINO Y et al.: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23RIL12RB2 regions associated with Behçet's disease. Nat Genet 2010;42:698-702.
42. JIA L, KOVACS JR, ZHENG Y, SHEN H, GAWALT ES, MENG WS: Expansion of Foxp3-expressing regulatory T cells in vitro by dendritic cells modified with polymeric particles carrying a plasmid encoding interleukin-10. Biomaterials 2008;29:1250-1261.
43. RONCAROLO MG, GREGORI S, BATTAGLIA M, BACCHETTA R, FLEISCHHAUER K, LEVINGS MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
44. HAUGEBERG G, VELKEN M, JOHNSEN V: Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004;63:744-745.
45. OHNO S, NAKAMURA S, HORI S et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-1368.
46. SCHIFFELERS RM, XU J, STORM G, WOODLE MC, SCARIA PV: Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 2005;52:1314-1318.
47. CHOI B, HWANG Y, KWON HJ et al.: Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008;52:87-97.
48. AKDENIZ N, ESREFOGLU M, KELES MS, KARAKUZU A, ATASOY M: Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet's disease. Ann Acad Med Singapore 2004;33:596-599.
49. KALLEN KJ: The role of trans signalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 2002;1592:323-343.
50. HEINRICH PC, CASTELL JV, ANDUS T: Interleukin-6 and the acute phase response. Biochem 1990;265:621-636.
51. HIRANO T: Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62:60-65.
52. YAMAKAWA Y, SUGITA Y, NAGATANI T et al.: Interleukin-6 in patients with Behçet's disease. J Dermatol Sci 1996;11:189-195.
53. LINKSWANG CR, CHUANG CY, CHEN CY: Anticardiolipin antibodies and interleukin-6 in cerebrospinal fluid and blood of Chinese patients with neuro-Behçet's syndrome. Clin Exp Rheumatol 1992;10:599-602.
54. BARDAK Y, ARIDOGAN BC: The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm 2004;12:53-58.
55. SHIM J, BYUN HO, LEE YD, LEE ES, SOHN S: Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behçet's disease-like mouse model. Gene Therapy 2009;16:415-425.
56. CIRELLI R, HERNE K, MCCRARY M, LEE P, TYRING SK: Famciclovir: review of clinical efficact and safety. Antiviral Res 1996;29:141-151.
57. PERRY CM, WAGSTAFF AJ: Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpes simplex infection. Drugs 1995;50:396-415.
58. DAVIES UM, PALMER RG, DENMAN AM: Treatment with acyclovir does not affect orogenital ulcers in Behçet's syndrome: a randomized double blind trial. Br J Rheumatol 1988;27:300-302.
59. ASHTON RJ, ABBOT KH, SMITH GM, SUTTON D: Antiviral activity of famciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. J Antimicrob Chemother 1994;34:287-290.
60. WUTZLER P, ULBRICHT A, FARBER I: Antiviral efficacies of famciclovir, valaciclovir, and brivudin in disseminated herpes simplex virus type 1 infection in mice. Intervirology 1997;40:15-21.
61. SOHN S, BANG D, LEE ES, KWON HJ, LEE SI, LEE S: Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice. Br J Dermatol 2001;145:799-804.
62. PLUNKETT W, HUANG P, GANDHI V: Preclinical characteristics of gemcitabine. Anticancer Drugs 1995;6(Suppl. 6):7-13.
63. SCHIRMER M, GEISEN F, TIEFENTHALER M, KONWALINKA G: Differential effects of cladribine and gemcitabine on erythrocytic progenitors from patients with chronic myeloid leukemia. Leuk Res 1999;23:1121-1126.
64. MARGREITER R, FISCHER M, ROBERTS K et al.: Gemcitabine- a novel immunosuppressive agent -prevents rejection in a rat cardiac transplantation model. Transplantation 1999;68:1051-1053.
65. SOHN S, LUTZ M, KWON HJ, KONWALINKA G, LEE S, SCHIRMER M: Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades-Behçet's disease-like mouse model. Exp Dermatol 2004;13:630-634.
66. PERICO N, OSTERMANN D, BONTEMPELLI M et al.: Colchicine interferes with L-selectin and leukocyte function-asociated antigen-1 expression on human T lymphocytes and inhibits T cell activation. J Am Soc Nephrol 1996:7:594-601.
67. COCCO G, CHU DC, PANDOLFI S: Colchicine in clinical medicine. A guide for internists. Eur J Intern Med 2010;21:503-508.
68. WECHSLER B: Colchicine and Behçet's disease: an efficacious treatment finally recognized. Rev Med Interne 2002;23:355-356.
69. SAKANE T, TAKENO M: Novel approaches to Behçet's disease. Expert Opin Investig Drugs 2000;9:1993-2005.
70. MELIKOGLU MA, KACAR C, CORT A, YUCEL G, ASLAN M: Oxidase and oxygenase in regulation of neutrophil redox pathways in Behçet's disease patients. J Enzyme inhib med chem 2011;1-6.
71. BANG D, CHOI B, KWON HJ, LEE ES, LEE S, SOHN S: Rebamipide affects the efficiency of colchicine for the herpes simplex virusinduced inflammation in a Behçet's disease mouse model. Eur J Pharmacol 2008;598:112-117.
72. LEE ES, KIM YA, KWON HJ, BANG D, LEE S, SOHN S: Thalidomide upregulates macrophage inflammatory protein-1alpha in a herpes simplex virus-induced Behçet's diseaselike animal model. Arch Dermatol Res 2004;296:175-181.
73. SUZUKI Y, ICHIYAMA T, OHSAKI A, HASEGAWA S, SHIRAISHI M, FURUKAWA S: Antiinflammatory effect of 1alpha,25-dihydroxyvitamin D(3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol 2009;113:134-138.
74. 3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind study. Br J Dermatol 1994;131:57-63.
75. ZEHNDER D, QUINKLER M, EARDLEY KS et al.: Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008;74:1343-1353.
76. DO JE, KWON SY, PARK S, LEE ES: Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behçet's disease. Rheumatology (Oxford) 2008; 47: 840-8.
77. PEDERSEN LB, NASHOLD FE, SPACH KM, HAYES CE: 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res 2007;85:2480-2490.
78. SADEGHI K, WESSNER B, LAGGNER U et al.: Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 2006;36:361-370.
79. PRABHU ANAND S, SELVARAJ P, NARAYANAN PR: Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNFalpha positive T cell subsets in pulmonary tuberculosis. Cytokine 2009;45:105-110.
80. DELUCA HF, CANTORNA MT: Vitamin D: its role and uses in immunology. FASEB J 2001;15:2579-2585.
81. CHOI B, LEE ES, SOHN S: Vitamin D3 ameliorates herpes simplex virus-induced Behcet's disease-like inflammation in a mouse model through down-regulation of Toll-like receptors. Clin Exp Rheumatol 2011;29(Suppl. 67):S13-S19.